risperidone has been researched along with Cataract, Membranous in 4 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study." | 6.80 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. ( Baldycheva, I; Earley, W; Flach, AJ; Laties, AM; Pathak, S; Rak, I, 2015) |
| "Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study." | 2.80 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. ( Baldycheva, I; Earley, W; Flach, AJ; Laties, AM; Pathak, S; Rak, I, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balamurugan, R | 1 |
| Gupta, PC | 1 |
| Kashyap, H | 1 |
| Ram, J | 1 |
| Laties, AM | 1 |
| Flach, AJ | 1 |
| Baldycheva, I | 1 |
| Rak, I | 1 |
| Earley, W | 1 |
| Pathak, S | 1 |
| Patel, E | 1 |
| Gallego, JA | 1 |
| Valibhai, F | 1 |
| Phan, NB | 1 |
| Still, DJ | 1 |
| True, J | 1 |
1 trial available for risperidone and Cataract, Membranous
| Article | Year |
|---|---|
Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cataract; Dibenzothiazepines; Female; Humans; Male; M | 2015 |
3 other studies available for risperidone and Cataract, Membranous
| Article | Year |
|---|---|
Risperidone-induced cataract in a young female.
Topics: Antipsychotic Agents; Cataract; Female; Humans; Lens, Crystalline; Psychotic Disorders; Risperidone; | 2020 |
Bilateral cataracts in a young patient with bipolar disorder on treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cataract; Humans; Male; Risperidone | 2016 |
Cataracts and quetiapine.
Topics: Adult; Antipsychotic Agents; Cataract; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; | 2001 |